<DOC>
	<DOCNO>NCT02173782</DOCNO>
	<brief_summary>To demonstrate least one two dos Berodual® ( 50 µg fenoterol hydrobromide/20 µg ipratropium bromide 25 µg fenoterol hydrobromide/10 µg ipratropium bromide , 1 puff q.i.d ) administer via Respimat® give bronchodilator response inferior obtain one dose Berodual® ( 50 µg fenoterol hydrobromide/21 µg ipratropium bromide , 2 puff q.i.d ) administer via MDI safety profile least good COPD patient treat 12 week .</brief_summary>
	<brief_title>Comparison Safety Efficacy Berodual® Administered Via Respimat® Device With That Administered Via Metered Dose Inhaler ( MDI ) Patients With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<mesh_term>Fenoterol , ipratropium drug combination</mesh_term>
	<mesh_term>Fenoterol</mesh_term>
	<criteria>Age &gt; = 40 year Diagnosis COPD accord follow criterion : screening FEV1 &lt; = 65 % predict Screening FEV1/FVC &lt; = 70 % Smoking history &gt; 10 packyears ( packyear 20 cigarette per day one year equivalent Able train proper use MDI Respimat® Able train performance technically satisfactory pulmonary function test All patient must willing able sign inform consent accordance Good clinical Practice ( GCP ) local legislation History cardiovascular , renal , neurologic , liver endocrine dysfunction ( e.g . hyperthyreosis ) clinically significant . A clinically significant disease define one opinion investigator may either put patient risk participation study disease may influence result study patient 's ability participate study Patients recent ( &lt; = one year ) history myocardial infarction Tuberculosis indication treatment History cancer within last five year ( exclude basal carcinoma ) Patients undergone thoracotomy Current psychiatric disorder History lifethreatening pulmonary obstruction , cystic fibrosis bronchiectasis An upper low respiratory tract infection four week prior screen visit Patients know symptomatic prostatic hypertrophy bladder neck obstruction Patients know narrowangle glaucoma raise intraocular pressure Patients clinically significant abnormal baseline haematology , blood chemistry urinalysis , abnormality defines disease list exclusion criterion Patients : Serum glutamic oxaloacetic transaminase ( SGOT ) serum glutamic pyruvic transaminase ( SGPT ) &gt; 200 % upper limit normal range Bilirubin &gt; 150 % upper limit normal range Creatinine &gt; 125 % upper limit normal range Patients chronic oxygen therapy Intolerance aerosolise ipratropium fenoterolcontaining product , hypersensitivity MDI ingredients Oral corticosteroid mediation dose great 10 mg prednisolone per day equivalent Betablocker medication Changes pulmonary therapeutic plan within last four week prior screen visit ( include withhold medication screen visit ) Concomitant recent ( within last month ) use investigational drug History drug abuse and/or alcoholism Pregnant nursing woman woman childbearing potential use medically approve mean contraception Previous participation study ( i.e . allocate randomized treatment number ) Patients history asthma , allergic rhinitis atopy blood eosinophil count 600/mm3 ( repeat eosinophil count conduct patient ) patient antihistamine , antileukotrienes , sodium cromoglycate nedocromil sodium Patients unable comply medication restriction specify section 4.2 use MDI without spacer</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>